C–H Oxidation by H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub> Catalyzed by a Non-Heme Iron Complex with a Sterically Encumbered Tetradentate N-Donor Ligand
作者:Qiao Zhang、John D. Gorden、Christian R. Goldsmith
DOI:10.1021/ic402501k
日期:2013.12.2
substrates, the neopentyl groups destabilize the metal-based oxidants generated from H2O2 and the Fe(II) complex. The presence of benzylic substrates with weak C–H bonds stabilizes an intermediate which we have tentatively assigned as a high-spin ferric hydroperoxide species. The oxidant generated from O2 reacts with allylic and benzylic C–H bonds in the absence of a sacrificial reductant; less substrate
的化合物Ñ,N' -dineopentyl- Ñ,Ñ ' -双(2-吡啶基甲基)-1,2-乙二胺(dnbpn)及其亚铁复杂的[Fe(dnbpn)(OTF)2 ]合成的。Fe(II)络合物用于催化H 2 O 2和O 2氧化烃。尽管H 2 O 2催化了烷烃的氧化与大多数先前报道的非血红素铁催化剂相关的那些相比,对叔碳显示出对仲碳而不是叔碳的更高的偏好,催化活性显着降低。除了将催化的氧化导向底物的较少拥挤的C–H键外,新戊基还使由H 2 O 2和Fe(II)络合物生成的金属基氧化剂不稳定。具有弱C–H键的苄基底物的存在稳定了一种中间体,我们暂时将其定为高纺氢过氧化铁物种。由O 2产生的氧化剂在不存在牺牲性还原剂的情况下与烯丙基和苄基CH键反应;与使用O 2作为末端氧化剂的相关先前描述的系统相比,观察到的底物脱氢更少。
Bicyclic androgen and progesterone receptor modulator compounds and methods
申请人:Zhi Lin
公开号:US20050288350A1
公开(公告)日:2005-12-29
The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.
NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE
申请人:Wong Michael K.
公开号:US20130012434A1
公开(公告)日:2013-01-10
The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
申请人:THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
公开号:US20160214097A1
公开(公告)日:2016-07-28
The invention provides simple small molecule, non-heme iron catalyst systems with broad substrate scope that can predictably enhance or overturn a Substrate Control Catalyst Control substrate's inherent reactivity preference for sp3-hybridized C—H bond oxidation. The invention also provides methods for selective aliphatic C—H bond oxidation. Furthermore, a structure-based catalyst reactivity model is disclosed that quantitatively correlates the innate physical properties of the substrate to the site-selectivities observed as a function of the catalyst. The catalyst systems can be used in combination with oxidants such as hydrogen peroxide to effect highly selective oxidations of unactivated sp3 C—H bonds over a broad range of substrates.